

**For Immediate Release**

**Alembic Pharmaceuticals Ltd.  
Consolidated Results for quarter ended 30.06.2011**

**Revenues up 34% at Rs 345 crores against Rs. 257 crores in PY  
PBT up 86% at Rs 35.47 crores against Rs. 19.08 crores in PY**

**Editors Synopsis**

- **Net sales up 34% at Rs 345 crores for the quarter against Rs. 257 crores.**
- **Domestic formulations sales up 19% for the quarter at Rs. 172 crores against Rs. 145 crores in corresponding period previous year**
- **International generics up 127% at Rs. 61 crores against Rs. 27 crores for the quarter.**
- **EBIDTA increases to 14.6% from 11.4% at Rs. 50.43 crores**
- **Net profit after tax for the quarter at Rs. 27.56 crores**

**Vadodara, 26<sup>th</sup> July, 2011**

This is first year of reporting separate numbers for Alembic Pharmaceuticals Limited and hence comparative financials of previous year are not available.

Alembic Pharmaceuticals Limited reported sales for the quarter ended June 30 2011 at Rs 344.72 crores up by 34% compared to Rs 256.62 crores in corresponding quarter previous year, while profit after tax for the quarter ended June 30, 2011 is Rs. 27.56 crores.

EBIDTA margins for quarter ended June 11 at Rs. 50.43 crores up at 14.6% from 11.4% for corresponding quarter last year.

### International Business

International Generics to the regulated markets grew by 127% to Rs. 61.15 crores from Rs. 26.97 Crores over corresponding quarter last year

Formulations sales to ROW markets grew by 71% to Rs. 11.32 crores from Rs. 6.61 crores.

Cumulative DMF filings at 54. Cumulative ANDA filings at 38. Cumulative ANDA approvals now stands at 15.

Four manufacturing plant undergo US FDA inspection during the quarter (3 API plants and 1 Formulation plant). During the quarter formulation plant also underwent ANVISA inspection.

### Domestic Business

**Domestic formulations** posted sales of Rs. 172.44 crores against Rs. 144.96 crores with a 19% growth over the corresponding quarter of the previous year.

Some of the specialty segments which the company entered recently are showing good progress as shown below.

(ORG IMS – June Growth %)

Therapy	Market Share	Therapy Growth	Alembic Growth
Gastro	2.08%	10%	19%
Cardio	1.08%	14%	26%
Anti Diabetic	1.20%	21%	28%
Gynaec	1.90%	15%	34%
Ophthal	1.12%	17%	24%

Alembic has four brands in the list of top 300 brands of the industry i.e. 'Azithral', 'Roxid', 'Althrocin', and 'Wikoryl'.

**Summary of total revenue (consolidated) for the quarter is as under:**

(Rs. in Lacs)

Particulars			
	Q1 FY12	Q1 FY11	% Change
<b>Formulation</b>			
Domestic	17244	14496	19%
International Branded	1132	661	71%
International Generics	6115	2697	127%
<b>API</b>			
Domestic	3475	1327	162%
International	6073	6269	(-)3%
Export incentives	433	212	104%
<b>Total</b>	<b>34472</b>	<b>25662</b>	<b>34%</b>

The previous year's sales figures are approx. and unaudited numbers of the relevant businesses which were then part of Alembic Limited. These are given merely for comparison to last year.

The Profit break-up for the quarter is as under:

(Rs. in Lacs)

<b>Particulars</b>	<b>Q1 FY12</b>	<b>% of Sales</b>
Operating Income	5043	14.6%
Profit Before Tax	3547	10.3%
Net Profit after Tax	2756	8.0%

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

**For more information:**

**Alembic Pharmaceuticals Limited**

**Mitanshu Shah**

**0265 – 3007630**

[mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)